Media stories about Antares Pharma (NASDAQ:ATRS) have been trending somewhat positive recently, according to Accern. The research firm identifies negative and positive media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Antares Pharma earned a news impact score of 0.08 on Accern’s scale. Accern also assigned news headlines about the specialty pharmaceutical company an impact score of 47.2032143187904 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Shares of ATRS stock opened at $2.11 on Friday. The company has a debt-to-equity ratio of 0.74, a quick ratio of 2.94 and a current ratio of 3.53. The firm has a market capitalization of $330.82, a PE ratio of -19.18 and a beta of 0.21. Antares Pharma has a 12 month low of $1.58 and a 12 month high of $4.09.
Antares Pharma (NASDAQ:ATRS) last announced its quarterly earnings data on Tuesday, March 13th. The specialty pharmaceutical company reported ($0.02) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.03) by $0.01. The business had revenue of $14.00 million for the quarter, compared to analyst estimates of $15.44 million. Antares Pharma had a negative net margin of 30.71% and a negative return on equity of 44.29%. The business’s quarterly revenue was down 1.4% on a year-over-year basis. analysts anticipate that Antares Pharma will post -0.07 earnings per share for the current fiscal year.
About Antares Pharma
Antares Pharma, Inc (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops and manufactures pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs.
Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter.